Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ANI Pharmaceuticals Stock Down 3.5 %

ANIP traded down $1.95 on Wednesday, reaching $53.88. The company's stock had a trading volume of 198,776 shares, compared to its average volume of 221,746. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -97.96 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.00 and a fifty-two week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average of $58.00 and a two-hundred day moving average of $60.17.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. During the same period in the previous year, the company earned $1.05 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 12.5% compared to the same quarter last year. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Franklin Resources Inc. increased its stake in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after purchasing an additional 691 shares during the period. Hohimer Wealth Management LLC acquired a new position in ANI Pharmaceuticals in the 3rd quarter valued at about $264,000. Geode Capital Management LLC raised its stake in ANI Pharmaceuticals by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock valued at $25,373,000 after acquiring an additional 17,314 shares during the last quarter. Barclays PLC lifted its position in ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after acquiring an additional 135,003 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $405,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ANIP shares. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.